Abilitech Medical Launches Assist, Designed to Help People with Muscular Dystrophy, Multiple Sclerosis and Spinal Cord Injury

Abilitech Medical Assist

Abilitech Medical Assist facilitates independent control of the arms by supporting and assisting both the shoulder and elbow for people with minimal strength. Software customizes the spring tension to lift objects such as a fork, phone, or water bottle, supporting items that weigh up to 12 ounces.

Those living with the limitations of upper-arm weakness and their caregivers can visit the Abilitech Medical website to schedule a confidential assessment to learn if the device can increase their independence and be referred to an Abilitech-trained clinic for a device fitting.

Abilitech assistive devices are designed to bring life-changing benefits to people with arm weakness:

  • Physical independence – Increases independence by assisting with activities such as eating, drinking, and using a computer.
  • Social independence – Increases the ability to more fully engage with others and participate in social events.
  • Economic benefits – May help decrease the reliance on caregivers and avoid or delay the need for a skilled nursing home — both services can be extremely expensive and are challenged by shrinking employee pools. Personal care assistants cost an average of $28,000 per year and assisted living costs can be up to $250,000 per year. In some cases, people using the Assist may even be able to return to work or stay in the workforce longer.

The Assist is the first in Abilitech’s future suite of products, which includes a powered handgrip device and a fully robotic voice-controlled arm-hand combination assistive device.

“We’ve worked with leading clinicians across the U.S.,” said Angie Conley, who founded Abilitech Medical in 2016 after time at Medtronic. “Equally as important, every week we work with people, their clinicians, and caregivers to get user feedback. This includes input from an engineer on our team who lives with a spinal cord injury.” Direct patient experience has led to optimal comfort, style, and weight of the device.

Abilitech is conducting clinical trials for the Assist at the University of Minnesota and Gillette Children’s Specialty Healthcare. Other organizations partnering with Abilitech to bring the product to market include Houston Methodist, Texas Children’s Hospital, HealthPartners, and Allina Health Courage Kenny Rehabilitation Institute.

“We’ve accumulated so many compelling stories that illustrate the patient need,” said Conley, who cites Dr. Hanry Samir, a cardiac anesthesiologist and critical care intensivist who lost his ability to work and perform simple functions after a stroke. Dr. Samir shared important feedback for the device.

“My dream is to be able to use my arm again, make things easier for my wife, and go back to the profession I love and live for,” said Samir.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”